All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network
During the EHA2021 Virtual Congress, the MPN Hub spoke with John Mascarenhas, Icahn School of Medicine at Mount Sinai, New York, US. We asked, What do phase II data show about the safety of imetelstat in relapsed/refractory myelofibrosis (MF)?
What do phase II data show about the safety of imetelstat in R/R MF?
In this video, Mascarenhas discusses the results of a safety analysis of imetelstat based on two phase II trials conducted in MDS (IMerge study) and MF (IMbark study) settings.
IMbark phase II study of imetelstat for R/R myelofibrosis: Updates from ASH 2020
Although Janus kinase (JAK) inhibition provides symptomatic relief for patients with myelofibrosis (MF), it does not induce long-term remission or alter disease course,...
ASH 2020 | Practice-changing abstracts in myeloproliferative neoplasms
The world-leading experts in MPN shared the top abstracts from ASH 2020 that they believe could have the greatest impact on clinical practice.
Subscribe to get the best content related to MPN delivered to your inbox